JPH09510456A - 同種リンパ球による癌の免疫療法 - Google Patents
同種リンパ球による癌の免疫療法Info
- Publication number
- JPH09510456A JPH09510456A JP7524180A JP52418095A JPH09510456A JP H09510456 A JPH09510456 A JP H09510456A JP 7524180 A JP7524180 A JP 7524180A JP 52418095 A JP52418095 A JP 52418095A JP H09510456 A JPH09510456 A JP H09510456A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- cells
- cell
- day
- lymphocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000735 allogeneic effect Effects 0.000 title claims abstract description 213
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 111
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 35
- 201000011510 cancer Diseases 0.000 title claims abstract description 21
- 238000009169 immunotherapy Methods 0.000 title description 15
- 210000004027 cell Anatomy 0.000 claims abstract description 235
- 238000000034 method Methods 0.000 claims abstract description 89
- 230000003211 malignant effect Effects 0.000 claims abstract description 56
- 238000001727 in vivo Methods 0.000 claims abstract description 54
- 230000036755 cellular response Effects 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims description 84
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 83
- 238000002560 therapeutic procedure Methods 0.000 claims description 52
- 230000000694 effects Effects 0.000 claims description 42
- 229940126530 T cell activator Drugs 0.000 claims description 35
- 230000004044 response Effects 0.000 claims description 32
- 210000004369 blood Anatomy 0.000 claims description 27
- 239000008280 blood Substances 0.000 claims description 27
- 208000032839 leukemia Diseases 0.000 claims description 27
- 238000012544 monitoring process Methods 0.000 claims description 18
- 206010025323 Lymphomas Diseases 0.000 claims description 15
- 239000012190 activator Substances 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 13
- 230000019491 signal transduction Effects 0.000 claims description 9
- 238000011476 stem cell transplantation Methods 0.000 claims description 9
- 206010061819 Disease recurrence Diseases 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 102000013462 Interleukin-12 Human genes 0.000 claims description 6
- 108010065805 Interleukin-12 Proteins 0.000 claims description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 6
- 108010047620 Phytohemagglutinins Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 239000011574 phosphorus Substances 0.000 claims description 6
- 230000001885 phytohemagglutinin Effects 0.000 claims description 6
- 108010062580 Concanavalin A Proteins 0.000 claims description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 5
- 230000011132 hemopoiesis Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 3
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 claims description 2
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 102000003816 Interleukin-13 Human genes 0.000 claims 4
- 108090000176 Interleukin-13 Proteins 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 150000004633 phorbol derivatives Chemical class 0.000 claims 2
- 239000002644 phorbol ester Substances 0.000 claims 2
- 230000003054 hormonal effect Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 abstract description 69
- 210000000130 stem cell Anatomy 0.000 abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 24
- 201000010099 disease Diseases 0.000 abstract description 23
- 230000036961 partial effect Effects 0.000 abstract description 21
- 238000000338 in vitro Methods 0.000 abstract description 16
- 230000003394 haemopoietic effect Effects 0.000 abstract description 9
- 238000011084 recovery Methods 0.000 abstract description 8
- 230000006044 T cell activation Effects 0.000 abstract description 5
- 230000009876 antimalignant effect Effects 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 description 64
- 208000009329 Graft vs Host Disease Diseases 0.000 description 59
- 241000699670 Mus sp. Species 0.000 description 57
- 210000002798 bone marrow cell Anatomy 0.000 description 46
- 210000001185 bone marrow Anatomy 0.000 description 40
- 238000010254 subcutaneous injection Methods 0.000 description 38
- 239000007929 subcutaneous injection Substances 0.000 description 38
- 241001465754 Metazoa Species 0.000 description 37
- 208000004736 B-Cell Leukemia Diseases 0.000 description 31
- 238000001802 infusion Methods 0.000 description 28
- 210000004989 spleen cell Anatomy 0.000 description 25
- 210000000265 leukocyte Anatomy 0.000 description 23
- 239000011886 peripheral blood Substances 0.000 description 21
- 210000005259 peripheral blood Anatomy 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 17
- 238000001990 intravenous administration Methods 0.000 description 17
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 16
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 229960001924 melphalan Drugs 0.000 description 16
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 16
- 229960001196 thiotepa Drugs 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 16
- 208000007660 Residual Neoplasm Diseases 0.000 description 14
- 210000001165 lymph node Anatomy 0.000 description 14
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 13
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 13
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 13
- 229960005420 etoposide Drugs 0.000 description 13
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 12
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 12
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 229960002092 busulfan Drugs 0.000 description 11
- 238000002512 chemotherapy Methods 0.000 description 11
- 239000012636 effector Substances 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 238000002054 transplantation Methods 0.000 description 11
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 9
- 229940086848 allopurinol 300 mg Drugs 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 229940047766 co-trimoxazole Drugs 0.000 description 9
- 230000003750 conditioning effect Effects 0.000 description 9
- 206010055113 Breast cancer metastatic Diseases 0.000 description 8
- 238000004820 blood count Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 238000010322 bone marrow transplantation Methods 0.000 description 7
- 229960004397 cyclophosphamide Drugs 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 6
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 190000008236 carboplatin Chemical compound 0.000 description 6
- 229960004562 carboplatin Drugs 0.000 description 6
- 230000036571 hydration Effects 0.000 description 6
- 238000006703 hydration reaction Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000007913 intrathecal administration Methods 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 206010002961 Aplasia Diseases 0.000 description 5
- 208000017604 Hodgkin disease Diseases 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000010836 blood and blood product Substances 0.000 description 5
- 229940125691 blood product Drugs 0.000 description 5
- 238000002659 cell therapy Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000004214 philadelphia chromosome Anatomy 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- 101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 description 4
- 102000000704 Interleukin-7 Human genes 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 230000008029 eradication Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 229940100994 interleukin-7 Drugs 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 4
- 239000005022 packaging material Substances 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000719 anti-leukaemic effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 230000003021 clonogenic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 102000055277 human IL2 Human genes 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000003836 peripheral circulation Effects 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000037821 progressive disease Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 206010025280 Lymphocytosis Diseases 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000026784 acute myeloblastic leukemia with maturation Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000004970 cd4 cell Anatomy 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 229940100602 interleukin-5 Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 206010053166 Candida sepsis Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical group [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699667 Mus spretus Species 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 description 1
- 210000000026 apposition eye Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 102000052622 human IL7 Human genes 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000009399 inbreeding Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000011459 intrathecal therapy Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000002261 nucleate cell Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000004594 persistent fetal circulation syndrome Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 108091008726 retinoic acid receptors α Proteins 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21494494A | 1994-03-17 | 1994-03-17 | |
| US08/214,944 | 1994-03-17 | ||
| PCT/US1995/003303 WO1995024910A1 (en) | 1994-03-17 | 1995-03-16 | Immunotherapy of cancer with allogeneic lymphocytes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH09510456A true JPH09510456A (ja) | 1997-10-21 |
| JPH09510456A5 JPH09510456A5 (enExample) | 2005-07-14 |
Family
ID=22801017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7524180A Pending JPH09510456A (ja) | 1994-03-17 | 1995-03-16 | 同種リンパ球による癌の免疫療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US5843435A (enExample) |
| EP (1) | EP0750505B1 (enExample) |
| JP (1) | JPH09510456A (enExample) |
| AU (1) | AU2100695A (enExample) |
| CA (1) | CA2184352A1 (enExample) |
| DE (1) | DE69533189T2 (enExample) |
| ES (1) | ES2224122T3 (enExample) |
| IL (1) | IL112969A (enExample) |
| WO (1) | WO1995024910A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002534083A (ja) * | 1998-12-31 | 2002-10-15 | ハダシット メディカル リサーチ サービス アンド デベロップメント リミテッド | 骨髄機能廃絶性ではない寛容原性の処置 |
| GB2484869A (en) * | 2009-08-17 | 2012-04-25 | Univ Tokyo | Pharmaceutical composition containing transiently surviving CTL |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112969A (en) * | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
| AU5930396A (en) * | 1995-05-25 | 1996-12-11 | Baxter International Inc. | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
| US5800539A (en) * | 1995-11-08 | 1998-09-01 | Emory University | Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease |
| US6805861B2 (en) * | 1996-01-17 | 2004-10-19 | Imperial College Innovations Limited | Immunotherapy using cytotoxic T lymphocytes (CTL) |
| US6213127B1 (en) | 1996-07-29 | 2001-04-10 | Emory University | Methods for treating cancer using allogeneic lymphocytes without graft vs host disease activity |
| US5834487A (en) * | 1996-09-24 | 1998-11-10 | Cv Therapeutics | Inhibition of 26S and 20S proteasome by indanones |
| EP1011694A4 (en) * | 1996-11-15 | 2000-11-15 | Baxter Int | TREATMENT FOR ALLOGENIC STEM CELL TRANSPLANTATION |
| EP1037643B1 (en) * | 1997-10-10 | 2003-12-03 | Meyer Pharmaceuticals, LLC | Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy |
| US20040033230A1 (en) * | 1997-12-24 | 2004-02-19 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6969518B2 (en) * | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US7598226B2 (en) | 1998-12-28 | 2009-10-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| WO2001040269A2 (en) * | 1999-11-30 | 2001-06-07 | Corixa Corporation | Compositions and methods for therapy and diagnosis of breast cancer |
| US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| JP4917201B2 (ja) * | 2000-12-04 | 2012-04-18 | 株式会社リンフォテック | 臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤、臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤、臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤ならびに臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤の製造方法。 |
| KR20020060643A (ko) * | 2002-06-04 | 2002-07-18 | 김진경 | 타인의 면역시스템을 이용하는 암의 치료 방법 |
| US20040175373A1 (en) * | 2002-06-28 | 2004-09-09 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| AU2003253684A1 (en) * | 2002-06-28 | 2004-01-19 | Xcyte Therapies, Inc. | Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| US20050112122A1 (en) * | 2003-09-02 | 2005-05-26 | Greiner Dale L. | Generation of hematopoietic chimerism and induction of central tolerance |
| WO2005079755A2 (en) * | 2004-02-12 | 2005-09-01 | Nektar Therapeutics | Interleukin-13 antagonist powders, spray-dried particles, and methods |
| EP1755685A4 (en) * | 2004-05-28 | 2008-11-12 | Mayo Foundation | METHODS FOR TRANSPLANTATION OF AUTOLOGOUS STEM CELLS |
| US9155789B2 (en) * | 2005-04-25 | 2015-10-13 | New York University | Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease |
| JP5638804B2 (ja) | 2006-08-04 | 2014-12-10 | アストラゼネカ アクチボラグ | ＥｒｂＢ２に対する抗体 |
| EP2942057A1 (en) | 2006-08-07 | 2015-11-11 | AbbVie Biotherapeutics Inc. | Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies |
| US7842293B2 (en) | 2006-08-07 | 2010-11-30 | Facet Biotech Corporation | Compositions and methods using anti-CS1 antibodies to treat multiple myeloma |
| EP2089042A2 (en) * | 2006-11-08 | 2009-08-19 | Aldagen, Inc. | Methods for improved engraftment following stem cell transplantation |
| WO2008067126A2 (en) * | 2006-11-08 | 2008-06-05 | Aldagen, Inc. | Methods for using aldhbr cells to supplement stem cell transplantation |
| DK2793914T3 (da) | 2011-12-22 | 2021-04-26 | Yeda Res & Dev | Kombinationsterapi til en stabil og langvarig transplantation |
| WO2016054354A1 (en) | 2014-10-02 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating malignancies |
| US10302644B2 (en) | 2014-11-04 | 2019-05-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
| EP4417210A1 (en) | 2017-03-15 | 2024-08-21 | Orca Biosystems, Inc. | Compositions and methods for hematopoietic stem cell transplants |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4690915A (en) * | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4861589A (en) * | 1987-03-23 | 1989-08-29 | Trustees Of Boston University | Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells |
| US5126132A (en) * | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
| JPH07102131B2 (ja) * | 1991-07-15 | 1995-11-08 | 日本石油株式会社 | ヒトリンパ球の癌細胞に対する傷害活性を高める方法 |
| IL112969A (en) * | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
-
1995
- 1995-03-13 IL IL11296995A patent/IL112969A/en not_active IP Right Cessation
- 1995-03-16 ES ES95913730T patent/ES2224122T3/es not_active Expired - Lifetime
- 1995-03-16 JP JP7524180A patent/JPH09510456A/ja active Pending
- 1995-03-16 WO PCT/US1995/003303 patent/WO1995024910A1/en not_active Ceased
- 1995-03-16 AU AU21006/95A patent/AU2100695A/en not_active Abandoned
- 1995-03-16 US US08/714,144 patent/US5843435A/en not_active Expired - Lifetime
- 1995-03-16 EP EP95913730A patent/EP0750505B1/en not_active Expired - Lifetime
- 1995-03-16 DE DE69533189T patent/DE69533189T2/de not_active Expired - Lifetime
- 1995-03-16 CA CA002184352A patent/CA2184352A1/en not_active Abandoned
-
1996
- 1996-10-23 US US08/735,496 patent/US5928639A/en not_active Expired - Lifetime
-
2001
- 2001-12-03 US US10/005,747 patent/US20020176850A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002534083A (ja) * | 1998-12-31 | 2002-10-15 | ハダシット メディカル リサーチ サービス アンド デベロップメント リミテッド | 骨髄機能廃絶性ではない寛容原性の処置 |
| GB2484869A (en) * | 2009-08-17 | 2012-04-25 | Univ Tokyo | Pharmaceutical composition containing transiently surviving CTL |
| JPWO2011021503A1 (ja) * | 2009-08-17 | 2013-01-24 | 国立大学法人 東京大学 | 一過性生着ｃｔｌを含む医薬品組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2224122T3 (es) | 2005-03-01 |
| CA2184352A1 (en) | 1995-09-21 |
| AU2100695A (en) | 1995-10-03 |
| WO1995024910A1 (en) | 1995-09-21 |
| DE69533189D1 (de) | 2004-07-29 |
| US5843435A (en) | 1998-12-01 |
| DE69533189T2 (de) | 2005-07-21 |
| US20020176850A1 (en) | 2002-11-28 |
| MX9604099A (es) | 1997-09-30 |
| IL112969A0 (en) | 1995-06-29 |
| IL112969A (en) | 2001-05-20 |
| US5928639A (en) | 1999-07-27 |
| EP0750505B1 (en) | 2004-06-23 |
| EP0750505A1 (en) | 1997-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH09510456A (ja) | 同種リンパ球による癌の免疫療法 | |
| US6544787B1 (en) | Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation | |
| EP0831860B1 (en) | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation | |
| US5443983A (en) | Method of culturing lymphocytes and method of treatment using such lymphocytes | |
| Escudier et al. | Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2 | |
| Brune et al. | Remission maintenance therapy with histamine and interleukin‐2 in acute myelogenous leukaemia | |
| CN115137752A (zh) | 用于干细胞移植的方法 | |
| Koretz et al. | Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer | |
| JP2002534083A (ja) | 骨髄機能廃絶性ではない寛容原性の処置 | |
| Ettinghausen et al. | The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2 | |
| JP3541950B2 (ja) | 癌およびウイルス性疾患を治療するための改変化ｔａｌｌ−１０４細胞の使用 | |
| US5702702A (en) | Modified cytotoxic tall cell line and compositions and methods for manufacture and use thereof as therapeutic reagents for cancer | |
| Kan et al. | Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract | |
| Miyazaki et al. | Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells | |
| Herberman | Therapy of cancer with interleukin-2-activated natural killer cells | |
| US5683690A (en) | Modified cytotoxic tall cell line and compositions and methods for manufacture and use thereof as therapeutic reagents for cancer | |
| JPWO2022216815A5 (enExample) | ||
| Yung et al. | Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease | |
| MXPA96004099A (en) | Immunotherapy of cancer with lymphocytes alogeni | |
| Lehn et al. | Bone marrow transplantation for chronic granulocytic leukemia | |
| Hayakawa et al. | Lymphokine-activated killer traffic assay and our preliminary clinical results of regional arterial infusion of lymphokine-activated killer cells for renal cell carcinoma | |
| Kubota et al. | Locoregional immunotherapy of head and neck cancers utilizing allogeneic spleen cells—a report of 2 cases | |
| WO1995032729A1 (en) | Short-term anti-cd3 stimulation of lymphocytes to increase their in vivo activity | |
| Kloosterman | Graft-versus-leukemia: applicable in the treatment of leukemia with bone marrow transplantation?: preclinical studies in rat models relevant for human acute leukemia | |
| Humphrey | 1. Role of Natural Killer (NK) Cells in Resistance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041020 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20041020 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20050106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050415 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060418 |